23ME-01473

23ME-01473 (threefold serial dilutions; 37°C) binds to purified hULBP6, hULBP2 and hULBP5 proteins with high affinity, among which it shows the strongest affinity for hULBP6 (K_D = 0.053 nmol/L), and does not bind to ULBP1, ULBP3 or ULBP4^[1].
23ME-01473 (three-fold serial dilution; room temperature) potently blocks the binding of purified ULBP5 and ULBP6-02 to purified NKG2D, with a stronger inhibitory effect on ULBP6-02 (IC₅₀ = 0.04 nmol/L) than on ULBP5 (IC₅₀ = 0.31 nmol/L)^[1].
23ME-01473 (threefold serial dilutions; 37°C) binds to purified activated hFcγ receptors with high affinity, particularly FcγRIIIa-V176 (K_D = 6.74 nmol/L) and FcγRIIIa-F176 (K_D = 25.50 nmol/L), while it shows low affinity for the inhibitory FcγRIIb^[1].
23ME-01473 (0.05-200 nmol/L) significantly enhances IFNγ production by hPBMCs pre-stimulated with IL-2/IL-15 and co-cultured with COV644 cells and soluble ULBP6-02, and its activity is superior to that of the Fc-WT anti-ULBP6/ULBP2/ULBP5 variant^[1].
23ME-01473 (100 nmol/L; 5 days) potently enhances the cytotoxicity of IL-2/IL-15-prestimulated hPBMC against COV644-GFP ovarian cancer cells in the presence of soluble ULBP6-02, and its activity is superior to that of effector function-impaired antibodies and isotype control antibodies^[1].
23ME-01473 (0.0001-10 nmol/L; per assay protocol) potently induces antibody-dependent cell-mediated cytotoxicity (ADCC) against COV644 ovarian cancer cells via activating FcγRIIIa, and its activity is significantly higher than that of the Fc-WT anti-ULBP6/2/5 variant^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.